Loading
The mu-opioid receptor is the target of morphine and the other strong opioids that control most severe cancer pain; the same receptor in the gut causes opioid constipation, which methylnaltrexone and naloxegol relieve by blocking it outside the brain. This dossier gathers the 2 products (2 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A Gi-coupled G-protein-coupled receptor that closes calcium channels and opens potassium channels in neurons, reducing neurotransmitter release; densely expressed in dorsal horn, periaqueductal grey and enteric neurons.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: mu-opioid receptor in pain pathways and gut. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Small molecule 1 | |
| Small-molecule opioid analgesic 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
MNTX 302 NCT00402038 | 3 | Positive | Advanced illness with opioid-induced constipation despite stable opioids and laxatives: subcutaneous methylnaltrexone 0.15 mg per kilogram every other day for two weeks versus placebo | Laxation within four hours of the first dose 48% vs 15% on placebo; laxation after two or more of the first four doses 52% vs 8% (P<0.001 for both). | |
| 3 | Completed | Prospective Randomized Clinical Trial to Evaluate the Use of Paravertebral Blocks in Reconstructive Breast Surgery | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Mu-opioid receptor" OR ABSTRACT:"Mu-opioid receptor" OR TITLE:"OPRM1" OR ABSTRACT:"OPRM1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mu-opioid receptor, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/oprm1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/oprm1.json. Licence CC BY-NC 4.0.